Kintor Pharmaceutical Limited (9939.HK)

HKD 1.12

(1.82%)

Market Cap (In HKD)

484.92 Million

Revenue (In HKD)

-

Net Income (In HKD)

-1.06 Billion

Avg. Volume

3.58 Million

Currency
HKD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.79-1.98
PE
-3.03
EPS
-0.37
Beta Value
-0.098
ISIN
KYG5273B1077
CUSIP
G5273B107
CIK
-
Shares
432965648.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Youzhi Tong
Employee Count
-
Website
https://www.kintor.com.cn
Ipo Date
2020-05-22
Details
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, engages in developing and commercializing a pipeline of small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs in the People's Republic of China and internationally. The company's products pipeline include Proxalutamide, a second generation androgen receptor (AR) antagonist for the treatment of metastatic castration-resistant prostate cancer, AR positive breast cancer, and COVID-19; and Pyrilutamide, an AR antagonist for the androgenetic alopecia (AGA) and acne vulgaris treatment. Its products pipeline also comprise ALK-1 antibody for the treatment of metastatic hepatocellular carcinoma (HCC) and various solid tumours; GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris; and PD-L1/TGF-ß, a dual target antibody to treat non-small cell lung cancer, biliary tract cancer, triple negative breast cancer, and HPV-associated tumours. In addition, the company's products pipeline include Detorsertib for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and HCC; and Hedgehog/SMO Inhibitor, an inhibitor of the hedgehog signal transduction pathway to treat blood cancer and basal-cell carcinoma. Kintor Pharmaceutical Limited was founded in 2009 and is headquartered in Suzhou, the People's Republic of China.